Working… Menu

Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04951141
Recruitment Status : Recruiting
First Posted : July 6, 2021
Last Update Posted : July 6, 2021
Information provided by (Responsible Party):
Beijing Immunochina Medical Science & Technology Co., Ltd.

Brief Summary:
Objective to study the safety and preliminary efficacy of intratumoral injection of CAR-T cells in the treatment of advanced liver tumors.

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma , Cholangiocarcinoma Biological: anti-GPC3 CAR-T cells Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Beijing Immunochina Medical Science & Technology Co., Ltd.
Actual Study Start Date : January 1, 2019
Estimated Primary Completion Date : September 30, 2023
Estimated Study Completion Date : December 21, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Cancer

Arm Intervention/treatment
Experimental: anti-GPC3 CAR-T Biological: anti-GPC3 CAR-T cells
A single arm, open-label pilot study is designed to determine the safety and efficacy of anti-GPC3 CAR-T cells in patients with GPC3-positive advanced liver cancer.

Primary Outcome Measures :
  1. Adverse events attributed to the administration of the anti-GPC3 CAR-T cells [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: 2 years ]
  2. Overall survival (OS) [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 69 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • GPC3 expression was positive by histological examination;
  • 18-69 years old;
  • The patients with advanced liver tumor who can not be operated and the effect of chemotherapy is poor;
  • The patients who received traditional palliative therapy had an expected survival period of more than 4 months;
  • Organ status allows clinical application.a. Creatinine < 1.5mg/dl; b. Cardiac ejection index > 55%; c. Heme > 9g / dl, bilirubin < 2.0mg/dl;
  • No bleeding and coagulation disorders were found;
  • There was no allergy to contrast medium;
  • Contraception: contraceptive measures were taken during clinical application and within 3 months after the last cells transfusion;
  • There is no other contraindication for lymphocyte collection;
  • Sign informed consent.

Exclusion Criteria:

  • Pregnant or lactating women;
  • Patients need systemic steroids therapy;
  • At present, the treatment conditions are as follows : a. Within 30 days before the collection of peripheral blood mononuclear cells,patiens were in other anti-tumor clinical observation period; b. Patients have not recovered from the acute side effects of previous treatment;
  • Patients received radiotherapy within 4 weeks after enrollment;
  • Patients received other cell modification therapy in the early stage;
  • In the screening stage, patients with lymphocyte transfection rate less than 5%, or T cell culture can not expand (< 5 times) patients;
  • Uncontrolled symptoms or other diseases include, but are not limited to, infection, congestive heart failure, unstable angina pectoris, arrhythmia, psychosis, or limiting the social environment that meets the requirements, or the researchers believe that they may bring unpredictable risks;
  • Patients with severe acute allergic reactions;
  • Patients who participated in other clinical trials;
  • Researchers believe that patients are not suitable to participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04951141

Layout table for location contacts
Contact: Fei Wu +8615801390058

Layout table for location information
The Fifth Medical Center of Chinese PLA General Hospital Recruiting
Beijing, China, 100039
Contact: Yin ying Lu, M.D.   
Sponsors and Collaborators
Beijing Immunochina Medical Science & Technology Co., Ltd.
Layout table for investigator information
Principal Investigator: Yin ying Lu, M.D. Beijing 302 Hospital
Layout table for additonal information
Responsible Party: Beijing Immunochina Medical Science & Technology Co., Ltd. Identifier: NCT04951141    
Other Study ID Numbers: 2017-003-D
First Posted: July 6, 2021    Key Record Dates
Last Update Posted: July 6, 2021
Last Verified: June 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases